Exploring Durable Remission With Rituximab in Antineutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis
Status:
Recruiting
Trial end date:
2025-04-01
Target enrollment:
Participant gender:
Summary
Rationale: Most recent insights in the treatment for patients with ANCA-associated vasculitis
(AAV) have demonstrated that 'tailored' maintenance treatment with rituximab (RTX) is
effective to achieve durable remission of disease. As such, RTX re-treatment can be tailored
on the basis of relevant immunological parameters that reflect minimal residual autoimmunity
(MRA) in AAV patients. Now, the present study intends to evaluate whether combining rituximab
with cyclophosphamide is superior to current standard of care with rituximab only to induce a
favorable immunological state of MRA in AAV patients that can beneficially influence, i.e.
reduce, the necessity of tailored re-treatment with rituximab